Navigation Links
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Date:6/3/2009

PARIS and BRISBANE, California, June 3 /PRNewswire-FirstCall/ --

- Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage.

In this study, 116 women with metastatic TNBC, defined as tumors lacking expression of estrogen and progesterone receptors and without overexpression of HER2, were randomly assigned to receive GC in combination with the investigational agent BSI-201 or GC alone. Patients assigned to receive chemotherapy without BSI-201 were allowed to receive BSI-201 at the time of disease progression.

The primary study endpoint was the rate of clinical benefit, defined as complete or partial response or stable disease of at least 6 months. Secondary study endpoints included progression-free survival, overall survival and safety.

Approximately 62 percent of patients receiving BSI-201 in combination with GC showed clinical benefit, compared with 21 percent in the group receiving chemotherapy alone (p= 0.0002). Tumor response (complete or partial response) was observed in 48 percent of patients who received BSI-201 combined with chemotherapy, whereas patients receiving chemotherapy alone showed a response rate of 16 percent. Women who received BSI-201 had a median progression-free survival of 6.9 months and overall survival of 9.2 months compared with 3.3 and 5.7 months, respective
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
2. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
3. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
4. Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis
5. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
6. Premier Research Announces Milestone Investigational New Drug Application
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
9. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
10. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
11. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 17, 2014 With the recent ... function has come across several challenges in creating ... managing globalization.  The Medical ... dedicated to providing benchmarking and best practices across ... is a service composed of three stages: 1) ...
(Date:10/17/2014)...  Amgen (NASDAQ: AMGN ) today announced ... president of Gladstone Institutes and Gladstone,s Robert W. and ... are pleased to welcome Dr. Sandy Williams ... , chairman and chief executive officer of Amgen. "Dr. ... his direct experience in our industry will both be ...
(Date:10/17/2014)... , Oct. 17, 2014 Research ... "Research and Development Prospect of China Dialysis ... Based on the 2013 version, this ... policies about dialysis industry and the relevant effect ... about dialysis industry segmentations. Moreover, it analyzes Chinese ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... Incorporated (Nasdaq: ARAY ), a global leader in ... fourth quarter and fiscal year 2010, ended June 30, 2010. ... Accuray reported total revenue of $61.8 million, a 5.1 percent ... of $58.8 million. For the fiscal year ended June 30, ...
... 31 Reportlinker.com announces that a new market ... The Global Orthobiologics Market - Players, ... http://www.reportlinker.com/p0192725/The-Global-Orthobiologics-Market---Players-products-and-technologies-driving-change-2008.html The primary ... factors compared with allograft bone tissue is that ...
Cached Medicine Technology:Accuray Announces Results for Fourth Quarter and Fiscal Year 2010 2Accuray Announces Results for Fourth Quarter and Fiscal Year 2010 3Accuray Announces Results for Fourth Quarter and Fiscal Year 2010 4Accuray Announces Results for Fourth Quarter and Fiscal Year 2010 5Accuray Announces Results for Fourth Quarter and Fiscal Year 2010 6Reportlinker Adds The Global Orthobiologics Market - Players, products and technologies driving change 2008 2Reportlinker Adds The Global Orthobiologics Market - Players, products and technologies driving change 2008 3Reportlinker Adds The Global Orthobiologics Market - Players, products and technologies driving change 2008 4Reportlinker Adds The Global Orthobiologics Market - Players, products and technologies driving change 2008 5
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium organic ... to celebrate this month. October marks Italian Heritage Month – ... of Americans of Italian heritage and Italians in America. October ... its favorite Italian cocktails and encourages everyone to enjoy its ... it is only in a glass. , Punzoné continues ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... Having been working in the garment industry for ... needs. According to James, one of the company’s top designers, ... with high-low skirts that add beauty to them. Chiffon floor ... has unveiled its new selection of 2014 long prom dresses. ... new items are available in over 20 popular designs. The ...
(Date:10/19/2014)... Visual Impact Frequency Training - a ... to the public generating a frenzied buzz of ... community. The commotion surrounding the program's launch has ... an investigative review. , "Many gym-goers are familiar ... known as a training 'plateau' where they are ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... in Turkey leads to pajamas offering a solution to troublesome ... ... do night sweats and a summer in,Turkey have in common? For 49-year-old ... a business,manufacturing and designing a line of night sweat sleepwear called,Cool-jams., , ...
... notes and restructures balance sheet eliminating $21.5 million of Redeemable ... ... Inc.,("CTI" or the "Company") (Nasdaq: CTIC ; MTA) today announced that ... due 2012 and warrants to purchase 7,326,950 shares of common,stock, no par ...
... When national drug use trends among adolescents go up or ... also goes up or down. Among deviance-prone female youth, it ... of Prevention Science., The risk of marijuana use among deviance-prone ... use among adolescents. The risk among deviance prone girls, however, ...
... HORIZON? , Children with allergic asthma may benefit from ... that trigger asthma and, in turn, decrease asthma symptoms ... University of Genoa in Italy reviewed the results of ... involving sublingual immunotherapy (SLIT) for allergic asthma in children. ...
... Adults without,symptoms of chronic obstructive pulmonary disease (COPD) should ... a new,recommendation from the U.S. Preventive Services Task Force. ... online,in the Annals of Internal Medicine. It will appear ... COPD is a lung disease in which the ...
... pediatric obesity epidemic in U.S. , , MONDAY, March 3 (HealthDay ... reduced the amount of food they ate and helped them ... hope to the problem of childhood obesity in the United ... to 19 years old are overweight, a 45 percent increase ...
Cached Medicine News:Health News:Photo: Sweet Dreams From Turkey 2Health News:Photo: Sweet Dreams From Turkey 3Health News:Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes 2Health News:Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes 3Health News:Drug use trends affect risk of marijuana in deviance prone boys, but not girls 2Health News:Journal Chest -- March 2008 news briefs 2Health News:Journal Chest -- March 2008 news briefs 3Health News:Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry 2Health News:Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry 3Health News:Restricting TV and Computer Time Helps Kids Lose Weight 2
... MODULITH SLX is not only one of the ... versatile medical workstation. Apart from being designed for ... in the urinary tract, the MODULITH SLX can ... endourological therapies. It is equally suitable for the ...
... is designed to easily couple with ... coupling eliminates clumsy time consuming delays. ... well. Dorniers patented isocentric locating arm ... simple using the Dornier Relax+ table, ...
... and transportable, the Dornier Compact Delta lithotripsy system ... the patient. The systems shock source and C-arm ... and avoid the risk of misalignment. The therapy ... to its motorized lateral and horizontal movement and ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
Medicine Products: